Novex is developed by Saint-Joseph University.

What development phase is Novex in?

Novex is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Novex

Saint-Joseph University · FDA-approved active Small molecule Quality 2/100

Novex, marketed by Saint-Joseph University, is a drug with a key composition patent expiring in 2028. The primary strength of Novex lies in its current market presence, leveraging the patent protection to maintain exclusivity. The primary risk is the potential increase in competition post-2028, as generic versions may enter the market.

At a glance

Generic name	Novex
Sponsor	Saint-Joseph University
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Novex CI brief — competitive landscape report
Novex updates RSS · CI watch RSS
Saint-Joseph University portfolio CI